Sequence variation and immunologic cross-reactivity among Babesia bovis merozoite surface antigen 1 proteins from vaccine strains and vaccine breakthrough isolates
Related Experiment Video
Updated: Aug 16, 2026

Detection of Trypanosoma brucei Variant Surface Glycoprotein Switching by Magnetic Activated Cell Sorting and Flow Cytometry
Published on: October 19, 2016
Tanya Leroith1, Kelly A Brayton, John B Molloy
1Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA. tleroith@vetmed.wsu.edu
Abstract:
The Babesia bovis merozoite surface antigen 1 (MSA-1) is an immunodominant membrane glycoprotein that is the target of invasion-blocking antibodies. While antigenic variation has been demonstrated in MSA-1 among strains from distinct geographical areas, the extent of sequence variation within a region where it is endemic and the effect of variation on immunologic cross-reactivity have not been assessed. In this study, sequencing of MSA-1 from two Australian B. bovis vaccine strains and 14 breakthrough isolates from vaccinated animals demonstrated low sequence identity in the extracellular region of the molecule, ranging from 19.8 to 46.7% between the T vaccine strain and eight T vaccine breakthrough isolates, and from 18.7 to 99% between the K vaccine strain and six K vaccine breakthrough isolates. Although MSA-1 amino acid sequence varied substantially among strains, overall predicted regions of hydrophilicity and hydrophobicity in the extracellular domain were conserved in all strains examined, suggesting a conserved functional role for MSA-1 despite sequence polymorphism. Importantly, the antigenic variation created by sequence differences resulted in a lack of immunologic cross-reactivity among outbreak strains using sera from animals infected with the B. bovis vaccine strains. Additionally, sera from cattle hyperinfected with the Mexico strain of B. bovis and shown to be clinically immune did not cross-react with MSA-1 from any other isolate tested. The results indicate that isolates of B. bovis capable of evading vaccine-induced immunity contain an msa-1 gene that is significantly different from the msa-1 of the vaccine strain, and that the difference can result in a complete lack of cross-reactivity between MSA-1 from vaccine and breakthrough strains in immunized animals.
Insights
Babesia bovis merozoite surface antigen 1 (MSA-1) shows significant sequence variation in Australian isolates, leading to a lack of immune cross-reactivity and vaccine evasion. This highlights challenges in developing effective Babesia bovis vaccines.
Area of Science:
- Veterinary Parasitology
- Molecular Immunology
- Bovine Infectious Diseases
Background:
- Babesia bovis merozoite surface antigen 1 (MSA-1) is crucial for parasite invasion and a target for antibodies.
- Antigenic variation in MSA-1 is known between geographical strains, but intra-regional variation and its impact on immunity are unclear.
Purpose of the Study:
- To assess the sequence variation of Babesia bovis MSA-1 within Australia.
- To determine the effect of this variation on immunologic cross-reactivity and vaccine efficacy.
Main Methods:
- Sequencing of the MSA-1 gene from Australian B. bovis vaccine strains and breakthrough isolates.
- Analysis of sequence identity, hydrophilicity, and hydrophobicity in the extracellular domain.
- Testing immunologic cross-reactivity using sera from vaccinated and infected cattle.
Main Results:
- Low sequence identity (19.8-46.7% and 18.7-99%) observed in MSA-1's extracellular region between vaccine and breakthrough isolates.
- Conserved hydrophilicity/hydrophobicity patterns suggest conserved function despite sequence polymorphism.
- Sequence variation resulted in a lack of immunologic cross-reactivity, with vaccine sera failing to recognize breakthrough strains.
Conclusions:
- Babesia bovis isolates evading vaccine-induced immunity possess significantly divergent MSA-1 genes.
- Sequence differences in MSA-1 lead to a complete loss of cross-reactivity in immunized animals.
- The observed antigenic variation poses a significant challenge for developing broadly protective B. bovis vaccines.
Related Concept Videos
Cross-reactivity
Malaria

